Advances in Dermatology and Allergology
eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current Issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

Prevalence of the most common types of high-risk HPV and p16INK4a expression in the penile location of asymptomatic men in Poland

Emilia Pawłowska-Krajka
1
,
Adam Dorobek
1
,
Małgorzata Brzozowska
2
,
Joanna Olszańska
3
,
Maciej Przybylski
4

  1. Department of General, Oncological and Functional Urology, Medical University of Warsaw, Poland
  2. Department of Forensic Medicine, Medical University of Warsaw, Poland
  3. Department of Pharmaceutical Microbiology, Medical University of Warsaw, Poland
  4. Chair and Department of Medical Microbiology, Medical University of Warsaw, Poland
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2026.159131
Online publish date: 2026/02/10
Article file
- Prevalence.pdf  [0.17 MB]
Get citation
 
 
1. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-11.
2. Deshmukh AA, Tanner RJ, Luetke MC, et al. Prevalence and risk of penile human papillomavirus infection: evidence from the National Health and Nutrition Examination Survey 2013-2014. Clin Infect Dis 2017; 64: 1360-6.
3. Hebnes JB, Olesen TB, Duun-Henriksen AK, et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med 2014; 11: 2630-44.
4. Khoo SP, Shafii MKA, Bhoo-Pathy N, et al. Prevalence and sociodemographic correlates of anogenital human papillomavirus (HPV) carriage in a cross-sectional, multi-ethnic, community-based Asian male population. PLoS One 2021; 16: e0245731.
5. Lopez-Romero R, Iglesias-Chiesa C, Alatorre B, et al. HPV frequency in penile carcinoma of Mexican patients: important contribution of HPV16 European variant. Int J Clin Exp Pathol 2013; 6: 1409-15.
6. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196: 1128-36.
7. Gamboa-Hoil SI. Human papillomavirus in men. Rev Int Androl 2023; 21: 100325.
8. Bruni LAG, Serrano B, Mena M, et al. 2023 Human Papillomavirus and Related Diseases in Poland. Summary Report 10 March 2023.
9. Duro D, Bernard O, Della Valle V, et al. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995; 11: 21-9.
10. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
11. Rampias T, Sasaki C, Weinberger P, et al. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101: 412-23.
12. Ai L, Stephenson KK, Ling W, et al. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 2003; 16: 944-50.
13. Martins VA, Pinho JD, Teixeira Junior AAL, et al. P16INK4a expression in patients with penile cancer. PLoS One 2018; 13: e0205350.
14. Steinestel J, Al Ghazal A, Arndt A, et al. The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma. BMC Cancer 2015; 15: 220.
15. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-40.
16. Husman AMDR, Walboomers JMM, Vandenbrule AJC, et al. The use of general primers Gp5 and Gp6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76: 1057-62.
17. Sahiner F, Kubar A, Yapar M, et al. Detection of major HPVs by a new multiplex real-time PCR assay using type-specific primers. J Microbiol Methods 2014; 97: 44-50.
18. Spindler L, Etienney I, Abramowitz L, et al. Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice. Tech Coloproctol 2024; 28: 23.
19. Afonso LA, Cordeiro TI, Carestiato FN, et al. High risk human papillomavirus infection of the foreskin in asymptomatic men and patients with phimosis. J Urol 2016; 195: 1784-9.
20. Agras K, Doluoglu OG, Acikgoz ZC, et al. Detection of human papillomavirus subtypes harbored in the foreskin of asymptomatic boys: controlled study. J Pediatr Urol 2020; 16: 388e1-88e6.
21. Bosnjak Z, Peric M, Krizan IR, et al. Prevalence and genotype distribution of high-risk human papillomavirus (HR HPV) in male genital samples of Osijek-Baranja County. Coll Antropol 2013; 37: 1203-8.
22. Davarmanesh M, Jazayeri SM, Dezfulian M, et al. High risk genotype distribution of human papillomavirus (HPV) according to age groups in Iranian asymptomatic men. Infect Agent Cancer 2020; 15: 29.
23. Grussendorf-Conen EI, Meinhof W, de Villiers EM, et al. Occurrence of HPV genomes in penile smears of healthy men. Arch Dermatol Res 1987; 279 Suppl: S73-5.
24. Heidegger I, Pichler R, Muller B, et al. Is real-time PCR the correct method to evaluate the incidence of human papillomavirus in prepuces of asymptomatic boys and men? World J Urol 2014; 32: 1199-204.
25. Hippelainen M, Syrjanen S, Hippelainen M, et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993; 20: 321-8.
26. Kjaer SK, Munk C, Winther JF, et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1528-33.
27. Klinglmair G, Pichler R, Zelger B, et al. Prevalence of the human papillomavirus (HPV) expression of the inner prepuce in asymptomatic boys and men. World J Urol 2013; 31: 1389-94.
28. Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005; 14: 1710-6.
29. Takahashi S, Shimizu T, Takeyama K, et al. Detection of human papillomavirus DNA on the external genitalia of healthy men and male patients with urethritis. Sex Transm Dis 2003; 30: 629-33.
30. Verit A, Zeyrek FY, Mordeniz C, et al. Status of high-risk oncogenic human papillomavirus subtypes harbored in the prepuce of prepubertal boys. Urology 2012; 80: 423-6.
31. Walczak L, Dutkiewicz S, Marsza³ek A. Incidence and prevalence of multiple types of genital human papillomavirus (HPV) infection in men: a study in Poland. Ginekol Pol 2013; 84: 112-5.
32. Flores R, Lu B, Nielson C, et al. Correlates of human papillomavirus viral load with infection site in asymptomatic men. Cancer Epidemiol Biomarkers Prev 2008; 17: 3573-6.
33. D’Hauwers KW, Tjalma WA. Screening for human papillomavirus: is urine useful? Indian J Cancer 2009; 46: 190-3.
34. Jenkins A, Allum AG, Strand L, et al. Simultaneous detection, typing and quantitation of oncogenic human papillomavirus by multiplex consensus real-time PCR. J Virol Methods 2013; 187: 345-51.
35. Meneses Venceslau E, Bezerra MM, Mota Lopes AC, et al. HPV detection using primers MY09/MY11 and GP5+/GP6+ in patients with cytologic and/or colposcopic changes. J Brasil Patol Med Labor 2014; 50: 280-5.
36. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35: 1304-10.
37. Lee B, Lee SW, Kim DI, et al. HPV prevalence in the foreskins of asymptomatic healthy infants and children: systematic review and meta-analysis. Sci Rep 2017; 7: 7050.
38. Godoy AE, Mandelli J, Oliveira FH, et al. p16INK4 expression in precursor lesions of squamous cell cervical cancer related to the presence of HPV-DNA. Braz J Med Biol Res 2008; 41: 583-8.
39. Macedo AC, Grande AJ, Figueiredo T, et al. DNA high-risk HPV, mRNA HPV and P16 tests for diagnosis of anal cancer and precursor lesions: a systematic review and meta-analysis. EClinicalMedicine 2023; 62: 102128.
40. Ghossein RA, Dogan S, Cohen MA, et al. Histologic spectrum and outcome of Human papillomavirus (HPV)-associated oral cavity squamous cell carcinoma: a single center experience and a survey of The Cancer Genome Atlas (TGCA) cohort. Virchows Arch 2024; 485: 665-74.
41. Younes AI, Osunkoya AO, Gandhi JS, et al. Primary penile mesenchymal tumors: a clinicopathologic analysis of 48 cases. Hum Pathol 2025; 159: 105814.
42. Aden D, Zaheer S, Khan S, et al. Navigating the landscape of HPV-associated cancers: from epidemiology to prevention. Pathol Res Pract 2024; 263: 155574.
43. Leeman A, Jenkins D, Marra E, et al. Grading immunohistochemical markers p16(INK4a) and HPV E4 identifies productive and transforming lesions caused by low- and high-risk HPV within high-grade anal squamous intraepithelial lesions. Br J Dermatol 2020; 182: 1026-33.
44. Sand FL, Lindquist S, Aalborg GL, et al. The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis. Pathology 2025; 57: 276-84.
45. Vandermaesen K, Elst L, Xiu X, et al. Re: The prognostic value of p53 and Ki-67 expression status in penile cancer: a systematic review and meta-analysis. Eur Urol 2025: 88: 534-5.
46. Adimonye A, Stankiewicz E, Touche S, et al. The prognostic value of PIK3CA copy number gain in penile cancer. Urology 2018; DOI: 10.1016/j.urology.2018.03.056.
47. Heller M, Prigge ES, Kaczorowski A, et al. APOBEC3A expression in penile squamous cell carcinoma. Pathobiology 2018; 85: 169-78.
48. Panic A, Reis H, Wittka A, et al. The biomarker potential of caveolin-1 in penile cancer. Front Oncol 2021; 11: 606122.
49. Grass GD, Chahoud J, Lopez A, et al. An analysis of nectin-4 (PVRL4) in penile squamous cell carcinoma. Eur Urol Open Sci 2023; 49: 1-5.
50. Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol 2019; 29: 145-9.
51. Caldarella C, De Risi M, Massaccesi M, et al. Role of (18)F-FDG PET/CT in head and neck squamous cell carcinoma: current evidence and innovative applications. Cancers 2024; 16: 1905.
52. Scher B, Seitz M, Reiser M, et al. 18F-FDG PET/CT for staging of penile cancer. J Nucl Med 2005; 46: 1460-5.
53. Ottenhof SR, Vegt E. The role of PET/CT imaging in penile cancer. Transl Androl Urol 2017; 6: 833-8.
54. Salazar A, Junior EP, Sanchez DF, et al. Assessing (18)F-FDG PET/CT uptake and its correlation with molecular biomarkers in penile cancer. Nucl Med Mol Imaging 2025; 59: 135-46.
55. Mbakaza O, Vangu MW. (18)F-FDG PET/CT imaging: normal variants, pitfalls, and artifacts musculoskeletal, infection, and inflammation. Front Nucl Med 2022; 2: 847810.
56. Pijl JP, Nienhuis PH, Kwee TC, et al. Limitations and pitfalls of FDG-PET/CT in infection and inflammation. Semin Nucl Med 2021; 51: 633-45.
57. Nyitray AG, Menezes L, Lu B, et al. Genital human papillomavirus (HPV) concordance in heterosexual couples. J Infect Dis 2012; 206: 202-11.
58. Benevolo M, Mottolese M, Marandino F, et al. HPV prevalence among healthy Italian male sexual partners of women with cervical HPV infection. J Med Virol 2008; 80: 1275-81.
59. Philibert P, Khiri H, Penaranda G, et al. High prevalence of asymptomatic sexually transmitted infections among men who have sex with men. J Clin Med 2014; 3: 1386-91.
60. Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health 2023; 11: e1345-62.
61. Garolla A, Mereu S, Pizzol D, et al. Papillomavirus infection and male infertility: a systematic review and meta-analysis. Health Sci Rep 2024; 7: e70048.
62. Kaspersen MD, Larsen PB, Ingerslev HJ, et al. Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One 2011; 6: e18095.
63. Perez-Soto E, Medel-Flores MO, Fernandez-Martinez E, et al. High-risk HPV with multiple infections promotes CYP2E1, lipoperoxidation and pro-inflammatory cytokines in semen of asymptomatic infertile men. Antioxidants 2022; 11: 1051.
64. Tangal S, Tasci Y, Pabuccu EG, et al. DNA fragmentation index and human papilloma virus in males with previous assisted reproductive technology failures. Turk J Urol 2019; 45: 12-6.
65. Tsen HF, Morgenstern H, Mack T, et al. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 2001; 12: 267-77.
66. Barnes KT, McDowell BD, Button A, et al. Obesity is associated with increased risk of invasive penile cancer. BMC Urol 2016; 16: 42.
67. Philippou P, Shabbir M, Ralph DJ, et al. Genital lichen sclerosus/balanitis xerotica obliterans in men with penile carcinoma: a critical analysis. BJU Int 2013; 111: 970-6
68. Torbrand C, Wigertz A, Drevin L, et al. Socioeconomic factors and penile cancer risk and mortality; a population-based study. BJU Int 2017; 119: 254-60.
69. Liao CI, Francoeur AA, Kapp DS, et al. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open 2022; 5: e222530.
70. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3: 22-31.
71. Morris BJ, Kennedy SE, Wodak AD, et al. Early infant male circumcision: systematic review, risk-benefit analysis, and progress in policy. World J Clin Pediatr 2017; 6: 89-102.
72. Skeppner E, Andersson SO, Johansson JE, et al. Initial symptoms and delay in patients with penile carcinoma. Scand J Urol Nephrol 2012; 46: 319-25.
73. Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016; 316: 2411-21.
74. Jit M, Brisson M. Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. Int J Cancer 2018; 143: 317-23.
75. WHO. Human papillomavirus vaccines: WHO position paper (2022 update). Weekly epidemiological record 2022; 50: 645-72.
76. Hartwig S, St Guily JL, Dominiak-Felden G, et al. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer 2017; 12: 19.
77. (2024). Proposal for a Council Recommendation on vaccine-preventable cancers (EC) EC. Brussels, Belgium. COM(2024) 45 final, 2024/0024 (NLE): 22.
78. (ECDC) ECfDPaC (2022). Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. Stockholm, Sweden, ECDC: 84.
79. Perez S, Tatar O, Gilca V, et al. Untangling the psychosocial predictors of HPV vaccination decision-making among parents of boys. Vaccine 2017; 35: 4713-21.
80. Shapiro GK, Tatar O, Knauper B, et al. The impact of publicly funded immunization programs on human papillomavirus vaccination in boys and girls: an observational study. Lancet Reg Health Am 2022; 8: 100128.
81. (2024). [Announcement of the Minister of Health of 3 October 2024 on the list of recommended vaccinations for which the purchase of vaccines is financed by the Minister responsible for health affairs]. Minister of Health RoP. Warsaw, Poland, Dziennik Urzêdowy Ministra Zdrowia. 2024.82.
82. Dorji T, Nopsopon T, Tamang ST, et al. Human papillomavirus vaccination uptake in low-and middle-income countries: a meta-analysis. EClinicalMedicine 2021; 34: 100836.
83. Han J, Zhang L, Chen Y, et al. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine 2025; 84: 103290.
84. 2025, [Report on vaccinations against the human papillomavirus (HPV)]. Retrieved 2025/07/06, from https://ezdrowie.gov.pl/portal/home/badania-i-dane/raport-o-szczepieniach-przeciwko-wirusowi-brodawczaka-ludzkiego-hpv.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.